



## **Icatibant Injection Now Available at Dramatically Lower Cost**

*Leucadia Pharmaceuticals' FDA-Approved Generic to FIRAZYR® Provides Full Therapeutic Equivalency*

**CARLSBAD, Calif.** –Patients and providers now have a new option in the treatment of acute attacks of hereditary angioedema (HAE) in adults at a dramatically lower cost with the launch of [Leucadia Pharmaceuticals](#) FDA-approved Icatibant Injection. The injection, which is AP-rated, bar-coded, preservative-free and does not contain natural rubber latex, is now available and is therapeutically equivalent to FIRAZYR® but at a fraction of the price.

“Those afflicted with HAE now have a better option to access this important drug,” said Dr. William Larkins, Chief Executive Officer of Leucadia Pharmaceuticals’ parent company, Custopharm. “Leucadia’s Icatibant Injection generic provides a long overdue, far more affordable option and it serves as yet another example of our commitment to expand patient access to safe, effective treatment solutions that increase quality of life without inducing financial hardship.”

A co-pay assistance card and medical information line are also available to patients. For more information on these additional benefits please visit [leucadiapharma.com](http://leucadiapharma.com).

Leucadia Pharmaceuticals was established in 2015 as a U.S. based innovator of generic drug products and represents the commercial arm of [Custopharm, Inc.](#) Leucadia continues to invest heavily to expand operations and scientific personnel while also pursuing partnerships and product acquisitions to provide important new generic injectable products to the acute and specialty markets and to reach communities and conditions that are under-served. Leucadia’s products include Dihydroergotamine Mesylate Nasal Spray; Sodium Tetradecyl Sulfate Injection (STS); Icatibant Injection; Dicyclomine HCl Injection, USP; Fludarabine Phosphate for Injection, USP; Pentobarbital Sodium Injection, USP; and Valrubicin Intravesical Solution, USP.

### **Contact**

Kara Eiseman  
Leucadia Pharmaceuticals  
844-538-2231  
[info@leucadiapharma.com](mailto:info@leucadiapharma.com)

FIRAZYR® is a registered trademark of Shire Orphan Therapies, GmbH.